Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.

T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res (2008) 1.61

Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51

Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med (2013) 1.40

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09

Modulation of antitumor responses by dendritic cells. Springer Semin Immunopathol (2005) 0.91

Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90

Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother (2010) 0.90

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. J Transl Med (2004) 0.86

Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. Cancer Immunol Immunother (2008) 0.86

Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology (2007) 0.84

Immune therapies. Hematol Oncol Clin North Am (2007) 0.81

Developing strategies in the immunotherapy of leukemias. Cancer Control (2013) 0.79

Incomplete tumour control following DNA vaccination against rat gliomas expressing a model antigen. Acta Neurochir (Wien) (2012) 0.75

Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology (2017) 0.75

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol (2008) 5.50

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol (2010) 5.20

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood (2005) 5.08

Perspective: Evolution and detection of genetic robustness. Evolution (2003) 4.10

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood (2004) 3.52

Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity (2004) 3.26

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol (2010) 3.17

Robustness can evolve gradually in complex regulatory gene networks with varying topology. PLoS Comput Biol (2007) 3.09

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood (2013) 3.03

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol (2007) 3.00

Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol (2013) 2.95

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood (2010) 2.87

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood (2004) 2.84

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol (2008) 2.77

Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol (2008) 2.74

Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet (2010) 2.66

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood (2002) 2.63

Cryptic genetic variation promotes rapid evolutionary adaptation in an RNA enzyme. Nature (2011) 2.63

Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res (2003) 2.62

CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood (2009) 2.45

Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood (2009) 2.43

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol (2011) 2.38

Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol (2003) 2.33

Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol (2014) 2.30

Asymmetric sequence divergence of duplicate genes. Genome Res (2003) 2.28

Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res (2008) 2.26

Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol (2010) 2.25

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol (2002) 2.23

Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res (2007) 2.21

Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol (2008) 2.20

Neutralism and selectionism: a network-based reconciliation. Nat Rev Genet (2008) 2.15

Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood (2013) 2.09

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood (2009) 2.09

Structure and evolution of protein interaction networks: a statistical model for link dynamics and gene duplications. BMC Evol Biol (2004) 2.01

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol (2009) 2.00

Assessing the longitudinal associations and stability of smoking and depression syndrome over a 4-year period in a community sample with type 2 diabetes 24. J Diabetes (2014) 1.98

Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood (2011) 1.97

Duplicate genes and robustness to transient gene knock-downs in Caenorhabditis elegans. Proc Biol Sci (2004) 1.94

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol (2012) 1.91

Convergent evolution of gene circuits. Nat Genet (2003) 1.89

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood (2009) 1.84

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica (2008) 1.80

Changes in perceived job strain and the risk of major depression: results from a population-based longitudinal study. Am J Epidemiol (2009) 1.79

Influence of metabolic network structure and function on enzyme evolution. Genome Biol (2006) 1.79

The robustness and evolvability of transcription factor binding sites. Science (2014) 1.76

Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate (2006) 1.74

Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica (2008) 1.72

Advances in specific immunotherapy for prostate cancer. Eur Urol (2007) 1.70

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica (2011) 1.68

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol (2012) 1.66

Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. Blood (2011) 1.64

Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol (2008) 1.63

Innate immunity--cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr Opin Immunol (2006) 1.62

High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol (2013) 1.60

Can peripheral blood γδ T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug effects of aminobisphosphonate therapy. J Bone Miner Res (2013) 1.59

Growth temperature and genome size in bacteria are negatively correlated, suggesting genomic streamlining during thermal adaptation. Genome Biol Evol (2013) 1.59

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol (2003) 1.58

Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol (2008) 1.55

Molecular evolution in large genetic networks: does connectivity equal constraint? J Mol Evol (2004) 1.55

Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol (2005) 1.54

Interventional therapy of bifurcation lesions: a TIMI flow-guided concept to treat side branches in bifurcation lesions--a prospective randomized clinical study (Thueringer bifurcation study, THUEBIS study as pilot trial). Circ Cardiovasc Interv (2009) 1.52

Severe accidental hypothermia with or without hemodynamic instability: rewarming without the use of extracorporeal circulation. Wien Klin Wochenschr (2002) 1.52

Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev (2010) 1.50

Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol (2013) 1.49

Project Ice Storm: prenatal maternal stress affects cognitive and linguistic functioning in 5 1/2-year-old children. J Am Acad Child Adolesc Psychiatry (2008) 1.49

Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. Br J Haematol (2006) 1.49

Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica (2005) 1.45

Evolutionary plasticity and innovations in complex metabolic reaction networks. PLoS Comput Biol (2009) 1.43

Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol (2012) 1.43

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood (2004) 1.41

Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophr Bull (2009) 1.40

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol (2010) 1.39

Export aspiration system in patients with acute coronary syndrome and visible thrombus provides no substantial benefit. Catheter Cardiovasc Interv (2007) 1.39

A latent capacity for evolutionary innovation through exaptation in metabolic systems. Nature (2013) 1.38

gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy (2005) 1.38

Synergism between lectins and vesicles of Viscum album L.- detection by biochemical and immunological methods. J Herb Pharmacother (2002) 1.38

Direct costimulatory effect of TLR3 ligand poly(I:C) on human gamma delta T lymphocytes. J Immunol (2006) 1.38

Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas. Oncol Rep (2005) 1.37

On the association between diabetes and mental disorders in a community sample: results from the German National Health Interview and Examination Survey. Diabetes Care (2003) 1.35

GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood (2006) 1.34

Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol (2009) 1.33

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood (2010) 1.33

Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol (2010) 1.32

Innate immune functions of human gammadelta T cells. Immunobiology (2007) 1.32

A model of protein translation including codon bias, nonsense errors, and ribosome recycling. J Theor Biol (2005) 1.32

Effects of a computer-based nursing documentation system on the quality of nursing documentation. J Med Syst (2007) 1.31

Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol (2010) 1.30

A statistical framework for combining and interpreting proteomic datasets. Bioinformatics (2004) 1.28

High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol (2008) 1.28

Specialization can drive the evolution of modularity. PLoS Comput Biol (2010) 1.27

Efficient characterization of high-dimensional parameter spaces for systems biology. BMC Syst Biol (2011) 1.26

Allogeneic transplantation in lymphoma: current status. Haematologica (2007) 1.25

Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J Allergy Clin Immunol (2011) 1.25

Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 1.25

GenomeHistory: a software tool and its application to fully sequenced genomes. Nucleic Acids Res (2002) 1.25

Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation. Blood (2010) 1.24